Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

Document Details

Document Type
Pub Defense Publication
Publication Date
Apr 01, 2016
Source ID
10.1016/s1470-2045(15)00613-0

Entities

People

  • Angela Demichele
  • Cynthia Huang Bartlett
  • Dennis Slamon
  • Hiroji Iwata
  • Igor Bondarenko
  • Jungsil Ro
  • Kathy Puyana Theall
  • Ke Zhang
  • Marco Colleoni
  • Maria Koehler
  • Massimo Cristofanilli
  • Nadia Harbeck
  • Nicholas C. Turner
  • Norikazu Masuda
  • Seock-ah Im
  • Sherene Loi
  • Sunil Verma
  • Yuqiu Jiang

Organizations

  • AstraZeneca
  • Daiichi Sankyo
  • Eli Lilly and Company
  • GSK
  • Novartis
  • Pfizer
  • United States Department of Defense
  • University of California, Los Angeles